Boehringer Ingelheim Chemicals Closing Virginia API Manufacturing Facility
The closure will impact 240 employees through a multistage process starting in December 2013.
Boehringer Ingelheim Chemicals Inc. (BICI) will close its Petersburg, Virginia plant at the end of 2014. According to an Aug. 15, 2013 BICI press release, the facility will continue normal operations through the remainder of 2013 and phase out operations the following year. The closure will impact 240 employees through a multistage process starting in December 2013.
The Petersburg facility manufactures active ingredients for the pharmaceutical industry. BICI’s parent company, Boehringer Ingelheim, conducted a review of its current manufacturing capabilities worldwide, as well as needs in the industry, and determined that it had more capacity than the marketplace can sustain. BICI considered selling the facility but was unable to find a buyer. The company said it will begin working with its customers immediately to ensure a smooth transition to new suppliers.
Source: Boehringer Ingelheim Chemicals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
